Date: 2017-07-11
Type of information: Joint-venture agreement
Compound:
Company: Enterome Bioscience (France) Nestlé Health Science (Switzerland) Microbiome Diagnostics Partners
Therapeutic area: Liver diseases - Hepatic diseases - Inflammatory diseases
Type agreement: joint-venture agreement
Action mechanism:
Disease: inflammatory bowel diseases, liver diseases.
Details:
- • On July 11, 2017, Enterome and Nestlé Health Science, announced the joint creation of Microbiome Diagnostics Partners (MDP). This company will bring together complementary, world-leading platforms and capabilities enabling the discovery and development of innovative diagnostics through to commercialization in multiple diseases areas, including inflammatory bowel diseases and liver diseases.
- MDP will be a 50/50 joint venture between Enterome and Nestlé Health Science. Enterome will contribute its current microbiome diagnostic programs and intellectual property derived from its unique microbiome-based platform for the development of diagnostics in all therapeutic areas except immuno-oncology. Prometheus Laboratories, a Nestlé Health Science company, will contribute its diagnostics development and commercialization expertise.
- Nestlé Health Science will invest €20 million in return for its 50% stake in MDP and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive further milestone payments linked to the success of clinical and commercial activities. MDP will be governed by a board, with Pierre Belichard, CEO of Enterome becoming Chairman. Warren Cresswell, General Manager and Head of Prometheus Diagnostics, will become a Board member of MDP and assume the role of MDP CEO.
- Initially, MDP will focus on developing diagnostics for the assessment and management of inflammatory bowel diseases based on Enterome’s IBD110 microbiome-derived mucosal healing biomarker and on the development of diagnostic products for progressive liver diseases [non-alcoholic fatty liver disease, (NAFLD), including non-alcoholic steatohepatitis (NASH)] based on Enterome’s MET210 biomarker. Prometheus will provide its serum-based biomarkers to both development programs.
Financial terms:
Latest news:
Is general: Yes
